---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-120864"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:13:53.260826+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAge reports FY2025 net loss $80.6M; positive BGE-102 Phase 1 data; $132M offering

## Summary
- Positive interim Phase 1 data for BGE-102: 86% median hsCRP reduction, 93% of obese participants reached <2 mg/L.
- Phase 2a cardiovascular trial planned 1H 2026; ophthalmology expansion with DME trial mid-2026.
- Completed $132.3M follow-on offering in Feb 2026; cash $285.1M at Dec 31, 2025, sufficient through 2029.
- FY2025: collaboration revenue $9.0M (vs $0); net loss $80.6M ($2.24/share) vs $71.1M ($6.63/share) in 2024.
- APJ agonist programs advancing; IND filing expected by end of 2026.

## SEC filing metadata
- accession: 0001193125-26-120864
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312526120864/0001193125-26-120864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312526120864/bioa-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-120864
- JSON: https://secwatch.observer/filing/0001193125-26-120864.json
- Plain text: https://secwatch.observer/filing/0001193125-26-120864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.